NCT06159790 2026-03-04
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Sandoz
Phase 3 Suspended
Clinical Trials
82 trialsNCT05378763 2026-02-18
PINNACLE
Spectrum Pharmaceuticals, Inc
Phase 3 Suspended
NCT06388902 2025-11-21
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
BioRay Pharmaceutical Co., Ltd.
Phase 1 Suspended
NCT05938296 2025-11-19
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
Phase 1 Suspended
NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
NCT05494697 2025-10-14
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
Phase 2 Suspended
NCT03417921 2025-10-01
Pancreatic
Ability Pharmaceuticals SL
Phase 1/2 Suspended
NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT05055518 2025-06-27
APL-102 Capsule in Patients With Advanced Solid Tumors
Apollomics Inc.
Phase 1 Suspended
NCT05958199 2025-06-27
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Phase 1 Suspended
NCT05603572 2025-06-05
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
Primocure Pharma
Phase 1/2 Suspended
NCT02354547 2025-05-30
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT05571969 2025-05-07
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Allarity Therapeutics
Phase 1 Suspended
NCT05191667 2025-02-13
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Suspended
NCT05416749 2024-11-20
A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Suspended
NCT05123534 2024-09-19
A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG
SonALAsense, Inc.
Phase 2 Suspended
NCT04946864 2024-08-19
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Suspended
NCT04120246 2024-07-10
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Veana Therapeutics
Phase 1 Suspended
NCT04714983 2024-04-09
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Phase 1 Suspended
NCT02546102 2024-04-03
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Precision Life Sciences Group
Phase 3 Suspended
NCT03932253 2024-03-27
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1 Suspended
NCT05067257 2024-03-18
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Sorrento Therapeutics, Inc.
Phase 2 Suspended
NCT05361915 2024-03-18
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
Sorrento Therapeutics, Inc.
Phase 2 Suspended
NCT05168904 2024-02-08
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Suspended
NCT05756556 2024-02-01
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
ImmVira Pharma Co. Ltd
Phase 2 Suspended
NCT04711161 2024-01-23
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Green3Bio, Inc.
Phase 1 Suspended
NCT04996030 2024-01-23
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Syros Pharmaceuticals
Phase 1 Suspended
NCT04505813 2024-01-16
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
NexImmune Inc.
Phase 1/2 Suspended
NCT04053062 2024-01-05
LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
Bioray Laboratories
Phase 1 Suspended
NCT04485052 2023-10-23
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Suspended
NCT03859752 2023-09-22
TR1801-ADC in Patients With Tumors That Express c-Met
Open Innovation Partners, Inc.
Phase 1 Suspended
NCT01796795 2023-09-14
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
G&E Herbal Biotechnology Co., LTD
Phase 2 Suspended
NCT03229876 2023-07-24
Safety and Efficacy Evaluation of CD19-UCART
Bioray Laboratories
Phase NA Suspended
NCT03002103 2023-04-26
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
SynCore Biotechnology Co., Ltd.
Phase 3 Suspended
NCT04650451 2023-04-20
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Bellicum Pharmaceuticals
Phase 1 Suspended
NCT01933815 2023-02-22
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Cortice Biosciences, Inc.
Phase 1/2 Suspended
NCT03208296 2023-02-06
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
Ascend Biopharmaceuticals Ltd
Phase 1/2 Suspended
NCT03906565 2023-01-10
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Suspended
NCT04042116 2022-12-20
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Clovis Oncology, Inc.
Phase 1/2 Suspended
NCT03322813 2022-08-03
ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma
InSightec
Phase NA Suspended
NCT01982175 2022-06-21
CLL004
Shanghai Zhangjiang Biotechnology Limited Company
Phase 2 Suspended
NCT03752541 2022-05-20
Efficacy and Safety Evaluation of BCMA-UCART
Bioray Laboratories
Phase NA Suspended
NCT04091711 2021-09-20
Evaluation of ReX-C® System for Medication Adherence in Oncology Patients Taking Oral Oncolytics
Dosentrx Ltd.
Phase NA Suspended
NCT04683120 2021-06-30
Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics
Laser LabCorp
Phase NA Suspended
NCT01562626 2021-05-12
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
Anaeropharma Science, Inc.
Phase 1/2 Suspended
NCT03722186 2021-03-22
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Suspended
NCT04001010 2021-02-05
SERENITY
Tetra Bio-Pharma
Phase 3 Suspended
NCT03381677 2020-08-03
POST
Innovative Surgical Designs
Phase NA Suspended
NCT03845907 2020-04-06
Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications
Seno Medical Instruments Inc.
Phase NA Suspended
NCT02356991 2019-11-04
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Suspended